Abiopharma

🔍 Swayze Eric (Executive)

Company: IONIS PHARMACEUTICALS INC (IONS)

Report Date: 2026-01-15

Detailed Transactions and Holdings:

• Acquired 21,366 shares of Common Stock (Direct)
  Date: 2026-01-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 51,819.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 9,884 shares of Common Stock at $75.34 per share (Direct)
  Date: 2026-01-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,935.00 | transaction_form_type: 4 | Footnotes: F2, F2, F3
• Acquired 111 shares of Common Stock (Direct)
  Date: 2026-01-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 367.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 49 shares of Common Stock at $75.97 per share (Direct)
  Date: 2026-01-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 318.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Acquired 25,800 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-01-15 | Code: A | Exercise: 2029-01-15 | equity_swap_involved: 0 | shares_owned_after: 90,282.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 21,366 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-15 | Code: M | Exercise: 2026-01-15 | equity_swap_involved: 0 | shares_owned_after: 39,251.00 | transaction_form_type: 4 | Footnotes: F6, F7, F7
• Acquired 9,675 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-15 | Code: A | Exercise: 2027-01-15 | equity_swap_involved: 0 | shares_owned_after: 48,926.00 | transaction_form_type: 4 | Footnotes: F8, F6, F7, F7
• Sold 111 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-15 | Code: M | Exercise: 2026-01-15 | equity_swap_involved: 0 | shares_owned_after: 386.00 | transaction_form_type: 4 | Footnotes: F6, F7, F7
• Acquired 225 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-15 | Code: A | Exercise: 2027-01-15 | equity_swap_involved: 0 | shares_owned_after: 611.00 | transaction_form_type: 4 | Footnotes: F9, F6, F7, F7

Footnotes:

• F1: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
• F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.26 to $75.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
• F4: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• F5: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
• F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
• F7: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
• F8: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• F9: Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.